Navigation Links
Onyx Pharmaceuticals Announces Positive Top-Line Carfilzomib Data From Phase 2b Study
Date:7/26/2010

linkTrackVars='prop5,eVar3,prop15';s.prop5='External Link';s.eVar3=s.prop5;s.prop15='99222084';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.onyx-pharm.com/view.cfm/32/Event-Calendar">http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

or by dialing 847-619-6547 and using the passcode 27571112.  A replay of the presentation will be available on the Onyx website or by dialing 630-652-3044 and using the passcode 27571112# approximately one hour after the teleconference concludes.  The replay will be available through August 9, 2010. 

About the Carfilzomib Development Program

Carfilzomib is a selective, next-generation proteasome inhibitor that has shown encouraging results in a broad clinical trial program in multiple myeloma.

As previously reported at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting, an ongoing, companion Phase 2 study, known as the 004 study, demonstrated encouraging overall response rates, tolerability and durable disease control when carfilzomib was administered as a single-agent in patients with relapsed and/or refractory multiple myeloma.  In 53 evaluable patients who had not been previously treated with bortezomib, carfilzomib achieved an overall response rate of 55 percent and a median duration of response of 11.5 months at 27mg/m2.  Forty percent of patients were refractory to their most recent therapy prior to entering the trial.  In the overall 004 study population, treatment with carfilzomib was well-tolerated, and no new or unexpected adverse events occurred. The most common Grade 3 treatment-emergent adverse events included: pneumonia (11 percent), anemia (9.7 percent), neutropenia (9.7 percent) and thrombocytopenia (9 percent). Peripheral neuropathy of any grade was infrequent, and no Grade 4 adverse
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide a Clinical Update on Carfilzomib
2. Alexza Pharmaceuticals Appoints Joseph L. Turner to Its Board of Directors
3. Poniard Pharmaceuticals Receives NASDAQ Deficiency Notice Related to Minimum Bid Price
4. Bayer HealthCare Pharmaceuticals Supports New Jersey Governors School in the Sciences at Drew University
5. Anadys Pharmaceuticals to Report Second Quarter 2010 Financial Results
6. Lotus Pharmaceuticals Terminates SEDA
7. Ampio Pharmaceuticals Announces Initiation of Phase II Clinical Trial of Optina™
8. China Yongxin Pharmaceuticals Inc. Announces the Expansion of Its Chain of Retail Stores to 110 Stores
9. Endo Pharmaceuticals to Announce Second Quarter 2010 Financial Results on July 30, 2010
10. Susquehanna Financial Group Hires Gary Nachman as Senior Analyst to Cover the Specialty Pharmaceuticals Sector
11. Endo Pharmaceuticals Completes Acquisition of HealthTronics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital ... AMGN ) announced today that they have ... validate new therapeutic targets and develop novel therapies ... that affects millions worldwide. The MGH-Broad-Amgen collaboration brings ... biology, human genetics, genomic technology, and drug discovery ...
(Date:1/15/2014)... FORT WORTH, Texas , Jan. 15, 2014 /PRNewswire/ ... "Lifetime in Dermatology Achievement Award" from the Journal ... Orlando Dermatology Aesthetic & Clinical Conference (ODAC). The event ... in Florida . ... comprehensive report on the practice of dermatology for clinical ...
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of ... able to protect their most important business ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Device Industry, it steadfastly remains one of ... involving IP infringement. This litigious nature can ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
... Inc. magazine has ranked Universal SmartComp #503 ... fourth annual Inc. 5000, an exclusive ranking of the ... comprehensive look at the most important segment of the ... 7-Eleven, Brooklyn Brewery, and Radio Flyer, maker of the ...
... SILVER SPRING, Md., Sept. 24 The U.S. ... an estrogen/progestin combined oral contraceptive that also contains ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) (Logo: ... a metabolite of folic acid, a water-soluble B-vitamin ...
Cached Medicine Technology:Universal SmartComp Ranks No. 503 Overall and No. 35 in the Health Sector on the 2010 Inc. 5000 with Three-Year Sales Growth of 600% 2Universal SmartComp Ranks No. 503 Overall and No. 35 in the Health Sector on the 2010 Inc. 5000 with Three-Year Sales Growth of 600% 3FDA Approves Combination Contraceptive Containing a Folate 2
(Date:4/15/2014)... States have nearly doubled since 1988, suggests new research ... with obesity apparently to blame for the surge. The ... has not hit all groups equally, with alarming increases ... According to new research reported in the April 15, ... , diabetes increased from 6 percent to 10 percent ...
(Date:4/15/2014)... have solved a decades-old medical mystery and in the ... invasive fungal infections, which kill about 1.5 million people a ... action of amphotericin, an antifungal drug that has been in ... is nearly as toxic to human cells as it is ... of the new findings appears in Nature Chemical Biology ...
(Date:4/15/2014)... School of Medicine have identified a mechanism that explains ... disease and why the virus is able to persist ... hard-to-kill pathogen, which infects an estimated 200 million people ... mitochondria dismantling the cell,s innate ability to fight ... , The study, published in today,s issue of the ...
(Date:4/14/2014)... children orphaned by HIV/AIDS in South Africa may provide ... emotional behavior issues in other areas of the world, ... research that could lead to successful interventions. , ... the United Nations mentions that due to the HIV/AIDS ... Sub-Saharan African, children are at an increased risk for ...
(Date:4/14/2014)... Va., USA The International and American Associations ... titled "Rare Bone Diseases and Their Dental, Oral, ... Sunday O. Akintoye, Andrea B. Burke, Alison M. ... Gafni, Janice S. Lee, Mary Scott Ramnitz, Martha ... in the OnlineFirst portion of the IADR/AADR ...
Breaking Medicine News(10 mins):Health News:Pre-diabetes and diabetes nearly double over the past 2 decades 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3Health News:Breaking bad mitochondria 2Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Rare bone diseases and their dental, oral and craniofacial manifestations 2
... Practice Arm of the School,s Department of Forensic ... Jan. 30 The Chicago School of ... its psychology services to the legal sector and ... thanks to its new Forensic Center, which was ...
... Kroger Co. (NYSE: KR ),said today it is ... stores,because the product was associated with peanut butter supplied by ... Stores under the following names in ... Kroger, Ralphs, Fred Meyer, Food 4 Less, Fry,s,King Soopers, ...
... grid of small arteries at the surface of the brain ... supply to tissue starved of nutrients and oxygen following a ... is optimistic news," said David Kleinfeld, a physics professor at ... flow in animal models of stroke. , Damage from stroke ...
... ) AMDL, Inc. (NYSE Alternext US: ADL), a vertically ... the US, announced today the second and final closing ... notes and warrants. The exclusive placement agent for ... on December 8, 2008, AMDL sold $1,077,500 of 12% ...
... school shootings, other tragedies , , FRIDAY, Jan. 30 (HealthDay ... people into hotheads. , A University of Kentucky study ... likely to view other people,s actions as hostile and ... , The researchers said their findings may help explain ...
... up bad lipoproteins, researchers say , , FRIDAY, Jan. ... (HDL) -- the "good" cholesterol -- may hold ... the deadly cardiovascular disease it can cause. , ... is close in size to natural HDL with ...
Cached Medicine News:Health News:New Chicago School of Professional Psychology Forensic Center Opens Doors to the Community 2Health News:New Chicago School of Professional Psychology Forensic Center Opens Doors to the Community 3Health News:Kroger Recalls Nut Topping Due to Possible Health Risk 2Health News:Mesh-like network of arteries adjusts to restore blood flow to stroke-injured brain 2Health News:AMDL, Inc. Announces Final Closing of Private Placement of Senior Notes 2Health News:AMDL, Inc. Announces Final Closing of Private Placement of Senior Notes 3Health News:Those Who Feel Rejected Direct Hostility Toward Others 2Health News:Synthetic HDL Could Fight Heart Disease 2
... Detection Reagents provide molecular labs a more ... By using our MGB technology, combined with ... now able to provide molecular labs more ... of specific organisms or genetic mutations associated ...
... MGB Alert Detection Reagents provide molecular labs ... based assays. By using our MGB technology, ... Nanogen is now able to provide molecular ... acid sequences of specific organisms or genetic ...
... and most advanced fecal occult blood test ... immunochemical FOBT (iFOBT) with high specificity and ... detect bleeding associated with more cancers and ... its superior specificity for lower GI bleeding, ...
... Capture vital signs faster, easier, ... Signs LXi, the latest innovation in ... With Spot LXi, you get more ... the flexibility to customize it to ...
Medicine Products: